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Mucosal immunity
CD8+ CTL avidityl mucosa are major sites of entry in natural HIV infection and therefore the
preferred sites to elicit high-avidity CD8+ CTL by vaccination. We directly compare systemic and mucosal
immunization in mice after DNA priming and boosting with rgp160 env expressed either in MVA or Ad for
their ability to induce mucosal as well as systemic HIV-speciﬁc CTL. The optimal CTL response in the gut
mucosa was observed after priming with the HIV-1 gp160 env DNA vaccine and boosting with rMVA or rAd
encoding the same envelope gene all administered intrarectally (IR). Maximum levels of high-avidity CD8+ T
cells were seen in intestinal lamina propria following this regimen. When the prime and boost routes were
distinct, the delivery site of the boost had a greater impact than the DNA priming. IM DNA prime and IR rMVA
boost were more effective than IR DNA prime and IM rMVA boost for eliciting mucosal CD8+ T-cell avidity. A
systemic DNA-prime-followed by systemic rMVA boost induced high levels of high-avidity CD8+ T cells
systemically, but responses were undetectable in mucosal sites. A single systemic immunization with rMVA
was sufﬁcient to induce high-avidity IFN-γ secreting CD8+ Tcells in systemic organs, whereas a single mucosal
immunization with rMVAwas not sufﬁcient to elicit high-avidity CD8+ T cells in mucosa. Thus, a heterologous
mucosal DNA prime-viral vectored boost strategy was needed. The requirement for a heterologous DNA
prime-recombinant viral boost strategy for generation of high-avidity CD8+ T cells in mucosal sites in mice
may be more stringent than for the induction of high-avidity CD8+ T cells in systemic compartments.
Published by Elsevier Inc.IntroductionThe AIDS pandemic has claimed over 40 million lives around the
world, and vaccination represents a promising approach to the preven-
tion of AIDS, especially in developing countries (Mwau andMcMichael,
2003; Nabel et al., 2002; Stover et al., 2007). Mucosal tissues are the
major site of natural HIV transmission and the reservoir for HIV
replication (Brenchley et al., 2004; Guadalupe et al., 2003; Mehandru
et al., 2004; Miller et al., 1989; Veazey et al., 1998; Zhang et al., 1999)
and dissemination. It is now well-documented that intestinal CD4+
CCR5+memory cells are the primary target for the virus and are rapidly
depleted in the gut of HIV-infected individuals (Brenchley et al., 2004;
Mehandru et al., 2004). The majority of mucosal memory CD4+ T cells
coexpress CCR5, the major coreceptor expressed by mucosally
transmitted strains of HIV and SIV (Mattapallil et al., 2005). After
vaginal SIV challenge, infection is localized to endocervical tissuetramural programs of the CCR,
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nc.during the ﬁrst 2–7 days without dissemination to the systemic
circulation (Spira et al., 1996; Zhang et al., 1999). Therefore, it would be
desirable to deliver a vaccine that induces resident mucosal CD8+ CTL
to rapidly deploy upon infection to limit viral replication and reduce
the natural reservoir within local mucosal tissues prior to systemic
dissemination (Belyakov et al., 2004a; Belyakov and Berzofsky, 2004;
Berzofsky et al., 2004a, 1999). Our previous studies (Belyakov et al.,
2001a, 2007a, 2006b) and studies by other groups (Baba et al., 2000;
Kaul et al., 2000; Kozlowski et al., 1997), demonstrated a strong
precedent for development of a mucosal AIDS vaccine to induce
sufﬁcient local immune responses (both mucosal CD8+ CTL and anti-
bodies) to prevent the steady andmassive spread of virus from the gut
mucosa into the systemic circulation. Current HIV-1 vaccines in Phase I
and II clinical trials aim to elicit CD8+ CTL in the hope that they may
prevent or reduce initial viral burden following infection and
dissemination of virus frommucosal sites into the systemic circulation.
An effective T-cell based HIV-1 vaccinewould reduce peak viral load in
the infected individual and subsequent disease course concomitant
with a reduction in transmission rate within the population at risk.
Systemic delivery of HIV-1 antigens by DNA prime heterologous viral
vector boost regimens has proven immunogenic in humans and
capable of eliciting multifunctional CD8+ CTL responses parenterally.
107I.M. Belyakov et al. / Virology 381 (2008) 106–115Although mucosal responses have been detected following systemic
delivery of HIV and SIV vaccines, it is unknown whether mucosal
responses generated by systemic delivery of heterologous prime-boost
vaccineswill prove effective as a defense atmucosal surfaces following
infection.
Different forms of heterologous prime-boost vaccines delivered
systemically are currently being tested in a number of ongoing pre-
clinical and clinical trials and hold signiﬁcant promise for eliciting
cellular responses and determining the efﬁcacy of T-cell based
vaccines (Allen et al., 2000; Amara et al., 2001; Barouch et al., 2000;
Belshe et al., 1998; Dale et al., 2006; Gherardi et al., 2003; Hel et al.,
2001b; Kent et al., 1998; Neeson et al., 2006; O'Neill et al., 2002;
Sharpe et al., 2003; Tritel et al., 2003; Wierzbicki et al., 2002; Wille-
Reece et al., 2006). Heterologous prime-boost immunization is a
proven strategy that elicits high frequencies of effector and memory T
cells, and in particular high-avidity CD8+ CTL that are relevant to
vaccine efﬁcacy (Alexander-Miller et al., 1996; Belyakov et al., 2007a,
2007b, 2006b; Derby et al., 2001; Estcourt et al., 2002; Gallimore et al.,
1998;Masopust et al., 2006; Ranasinghe et al., 2007). Amajor question
of current vaccine trials is whether the timing and kinetics as well as
the magnitude and quality of the response in vaccinated individuals is
sufﬁcient to have an impact on initial virus replication in the gut and/
or subsequent levels of viral load in peripheral blood.
We have attempted to address this question experimentally by
mucosal immunization in small animal models and SHIV protection
studies in rhesus macaques (Belyakov et al., 1998a, 2000, 2001a,
2007a, 2006b). In previous studies, we demonstrated that mucosal
vaccination of rhesus macaques with an HIV/SIV peptide vaccine was
more effective than a systemically delivered vaccine at clearing virus
following intrarectal SHIV challenge from the major reservoir of SHIV
replication in the intestinal mucosa (Belyakov et al., 2001a). Recently,
we showed that a mucosal vaccine capable of inducing high levels of
high-avidity mucosal CTLs can delay the appearance of acute-phase
peak viremia in macaques challenged intrarectally with pathogenic
SHIV, and this outcome correlated better with the magnitude of high-
avidity mucosal CTLs thanwith systemic CTLs (Belyakov et al., 2006b).
These data suggest a direct role for resident mucosal effector CD8+ CTL
in reducing initial virus burden and altering subsequent disease
course following mucosal infection. Furthermore, the preservation of
CD4+ T cells in intestinal lamina propria and the reduction of virus in
the gut correlated better with high-avidity mucosal CTL induced by
the mucosal vaccine (Belyakov et al., 2007a).
These results provide support for the development of mucosal
vaccines for HIV-1 that induce local mucosal high-avidity CD8+ CTL. A
direct comparison of different vaccine regimens to induce the most
optimal high-avidity CD8+ T-cell response in mucosal sites has not
been carried out. In this study, we ﬁnd that the generation of a high
level of systemic high-avidity CD8+ T cells is less dependent on a
heterologous prime-boost regimen and that a single immunization
with a recombinant viral vector is sufﬁcient to induce high levels of
systemic high-avidity CD8+ T cells. Systemic prime-boost immuniza-
tion signiﬁcantly improved the magnitude of the CD8+ T-cell response
but not the quality of these responses. In contrast, for mucosal im-
munization, the heterologous prime-boost strategy was more critical,
at least in mice, in order to induce high levels of mucosal high-avidity
CD8+ T cells. Interestingly, a DNA vaccine given intramuscularly can
also prime for a mucosal boost. In the current study we attempted to
address the avidity issue experimentally by comparingmucosal versus
systemic prime-boost immunization in small animalmodels. However,
some additional pre-clinical study in the SIV model in macaques is
needed prior to translation of our ﬁndings to an HIV clinical trial.
Results
To examine the inﬂuence of mucosal compared to systemic prime-
boost immunization on development of functional CTL responses, wetested four different prime-boost immunization strategies in a DNA
vaccine prime and rMVA or rAd boost, both encoding the HIV Env B
protein, for their effectiveness at inducing mucosal (Peyer's patch) as
well as systemic (spleen) HIV-speciﬁc CTL in mice. DNA priming
immunizations and recombinant vector boosts (rMVA or rAd) were
administered intrarectally (IR) or intramuscularly (IM) in combina-
tions, including 1) DNA and recombinant vector IM; 2) DNA IR and
recombinant vector injected IM; 3) DNA IM and recombinant vector
injected IR; 4) DNA and recombinant vector IR. Two additional groups
of animals received either the DNA immunization only or a single
immunization with recombinant virus. We used 3 consecutive DNA
immunizations (50 μg/per mouse per immunization) with 3 weeks
interval between each immunization and boosted mice with rMVA
(107 pfu) (Figs. 1A, B) or rAd (1010 pfu) (Figs. 1C, D). We found that the
systemic prime-boost approach for either virus (rMVA or rAd)
induced a high P18-I10 CTL response in the spleen (Figs. 1A, C).
However, the HIV-speciﬁc CTL response in Peyer's patches of immu-
nized animals was very low after systemic (IM) DNA-MVA prime-
boost immunizations (Fig. 1B). Similar results were observed when
rAd was used for boosting the DNA prime (Fig. 1D). An intrarectal DNA
prime followed by a systemic (IM) MVA or rAd boost induced very
high CTL responses in the spleen and a more modest CTL response in
Peyer's patches (Fig. 1). Similar to results observed in other studies
DNA immunization alone was not effective at eliciting a signiﬁcant
CTL response, and a single immunization with either recombinant
vaccinia or adenovirus elicited comparable and weak CTL responses in
both spleen and Peyer's patches. Thus, the heterologous prime-boost
strategy was effective at eliciting strong CTL in both sites; however,
delivery of either the prime or the boost through the mucosal route
improved the mucosal response. When the prime and boost routes
were distinct, in the majority of cases, the route of the boost had more
impact than the route of DNA priming. Thus, IM-IR was more effective
than IR-IM for PP responses (pb0.05) (Figs. 1B, D), whereas the
opposite was true for splenic responses (pb0.05) (Figs. 1A, C). There-
fore, it appears that DNA can cross-prime for a boost by either route.
The optimal CTL response in the gut mucosa was observed when
both priming with HIV DNA vaccine and boosting with recombinant
MVA were delivered through the intrarectal route (Fig. 1B; solid
triangles). Interestingly, although the mucosal CTL response was also
optimized when the DNA prime and rAd boost were both delivered
intrarectally, the response was signiﬁcantly less (pb0.01) than that
obtained with the DNA prime-recombinant MVA boost (Fig. 1B vs D;
ﬁlled triangles). It is important to note that a mucosal prime-boost
strategy with either recombinant virus also induced a signiﬁcant, P18-
I10-speciﬁc CTL response in the systemic circulation aswell (Figs.1A, C;
ﬁlled triangles) albeit less than a DNA prime viral vector boost
delivered by the same IM route. If extrapolatable to humans, these
results suggest that a heterologous prime-boost strategy delivered
through themucosal routemay be valuable to induce optimal mucosal
immunity available as a ﬁrst line of defense to limit replication of the
virus.
Because we found similar patterns of immunity with both rMVA
and rAd vector boosts, we carried out subsequent studies only with
rMVA as a boost. Since we and other groups have shown in several
different challenge models that high-avidity CTL are most effective at
clearing viral challenge in vivo (Alexander-Miller et al., 1996;
Belyakov et al., 2007a, 2006b; Derby et al., 2001; Gallimore et al.,
1998; Ranasinghe et al., 2007), we examined the inﬂuence of mucosal
prime-boost vs systemic prime-boost immunization on the develop-
ment of CD8+ T-cell avidity in mucosal and systemic compartments.
We compared the IR to the IM route of immunization for induction of
high-avidity CD8+ T cells following a DNA prime and rMVA boost. IR
prime-boost immunization induced a higher proportion of high-
avidity IFN-γ secreting CTLs in the GALT that could be activated at
low P18-I10 peptide concentration compared with IM immunized
animals in the same compartment (Fig. 2A vs C; ﬁlled diamonds). A
Fig. 1. The optimal CD8+ CTL response in the gut mucosa was observed after priming with DNA vaccine and boosting with HIV-1 rMVA or rAd both through the intrarectal route.
Groups of BALB/cmice (ﬁve per group) were primed IM or IR with HIV DNA 3 times at three-week intervals between each immunization and boostedwith HIV-1 rMVA (A, B) or HIV-1
rAd (C, D). Three weeks after the last immunization, SP (A, C) and PP (B, D) cells were stimulated in vitro for 7 days before assay. Cytolytic activity of CTL was measured by a 4-hr assay
with 51Cr-labeled targets. 51Cr-labeled P815 targets were tested in the presence or absence of P18-I10 peptide (1 μM). E:T 100:1 ratio means 100 effectors to 1 target. Negative control
values were subtracted from experimental lysis. SEM of triplicate cultures were all b5% of the mean.
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prime-boost immunization were observed after activation with high
(1 μM) and low (0.0001 μM) concentrations of P18-I10 peptide (Fig.
2A). IR immunization with rMVA alone (ﬁlled squares) induced a
comparable number of IFN-γ CD8+ T cells in Peyer's patches against
the high concentration of peptide (1 μM), but few cells responded by
production of IFN-γ to the lower concentration of P18-I10 peptide
(0.0001 μM) indicative of high-avidity CD8+ T cells (Fig. 2A). Thus, the
mucosal DNA prime-viral vectored boost strategy was necessary for
the generation of high-avidity CD8+ T cells in mucosal sites, whereas a
single mucosal immunization with the rMVA alone was not sufﬁcient
to produce the high-avidity CD8+ T-cell proﬁle. In contrast, the
necessity of the DNA prime in a heterologous prime-boost strategy
was less apparent for induction of high-avidity CD8+ T cells in the
spleen, when the heterologous prime-boost was delivered by the
intrarectal route (Fig. 2B). There was no signiﬁcant difference in the
peptide dose response curves seen in the spleen after IR prime-boost
immunization or rMVA immunization alone (pN0.05) (Fig. 2B). The
magnitude of the CD8+ immune responses in the spleen was slightly
greater when animals were given an IR prime-boost compared to a
single rMVA immunization (Fig. 2B), but the quality of response was
similar in that both groups responded with equal avidity to the lower
concentrations of peptide. In marked contrast to the mucosally
immunized animals, neither DNA prime rMVA boost nor rMVA alone
delivered by the IM route was capable of inducing high-avidity CD8+
T cells at the mucosal site (Fig. 2C). IM prime-boost and rMVA
immunization alone induced predominantly low-avidity CD8+ T cells
in Peyer's patches. High-avidity systemic (spleen) responses were
robust after IM immunization regardless of whether a prime-boost
strategy or a single rMVA immunization strategy was employed. The
magnitude of CD8+ IFN-γ secreting cells responsive to nanomolarconcentrations of P18-I10 peptide was equal in both cases (Fig. 2D).
Thus, even a single IM immunization with rMVA is sufﬁcient to
induce high-avidity CD8+ T cells in the spleen. Further, the avidity in
the spleen was slightly higher after IM than IR immunization. Thus,
although it is not surprising that a heterologous prime-boost
immunization is more effective than MVA alone, it was not previously
appreciated that this difference is much more dramatic after mucosal
immunization than after systemic immunization.
To quantify the CD8+ T-cell avidity differences among the groups
immunized through different routes in a prime-boost strategy, we
calculated the ratio (%) between the number of IFN-γ secreting cells
against a low (0.0001 μM) P18-I10 peptide concentration (reﬂecting
high-avidity CD8+ T cells) and the number of IFN-γ secreting cells
against a high (1 μM) concentration (reﬂecting both high- and low-
avidity CD8+ T cells) for the CD8+ T cells to the P118-I10 epitope (Figs.
2E–H). A higher ratio indicates the skewing of CD8+ T cells toward
high-avidity cells, whereas a lower value indicates skewing toward
low-avidity cells. A striking difference was seen in the avidity ratio in
Peyer's patches after the IR prime-boost regimen compared to IR
rMVA immunization alone (pb0.001) (Fig. 2E). Greater than 95% of
antigen-speciﬁc cells detected in the Peyer's patch were high avidity
following the IR prime-boost strategy whereas only 10% of the total
responding cells were high avidity in animals immunized with rMVA
alone. In contrast, none of the antigen-speciﬁc CD8+ IFN-γ secreting
cells detected in the mucosa (PP) following the IM prime-boost
immunization regimen were high-avidity CD8+ T cells (Fig. 2G). The
avidity ratio in spleen after IR immunization with prime-boost was
similar to the avidity ratio after IR immunization with rMVA alone
(pN0.05) (Fig. 2F). This fact indicates that the generation of high-
avidity CD8+ T cells in mucosal compartment can be highly
improved by the DNA prime-boost regimen, whereas generation
Fig. 2. Mucosal prime-boost immunization is essential for high-avidity CD8+ T cells in inductive mucosal sites (Peyer's patches), whereas a single systemic immunization with
recombinant vector was sufﬁcient to induce high-avidity CD8+ T cells in systemic sites. (A) CD8+ T-cell activity measured as IFN-γ-producing cells by ELISPOT as a function of peptide
concentration for HIV-1 P18-I10 peptide in the PP after IR DNA prime and rMVA boost (closed diamond) or rMVA alone (closed square). T cells were activated with different
concentrations of P18-I10 peptides (1, 0.01, 0.0001 μM and no peptide, as indicated). (B) IFN-γ-producing cells as a function of peptide concentration for HIV-1 P18-I10 peptide in the
SP after IR immunizationwith DNA prime and rMVA boost (closed diamond) or rMVA alone (closed square). (C) IFN-γ producing cells as a function of peptide concentration for HIV-1
P18-I10 peptide in the PP after IM immunizationwith DNA prime and rMVA boost (closed diamond) or rMVA alone (closed square). (D) IFN-γ producing cells as a function of peptide
concentration for HIV-1 P18-I10 peptide in the SP after IM immunizationwith DNA prime and rMVA boost (closed diamond) or rMVA alone (closed square). Error bars represent SD of
four mice/group. Ratio high/(high+ low) CD8+ T-cell avidity (E–H). (E, G) PP; (F, H) SP. Ratio of the number of IFN-γ+ cells against 0.0001 μM peptide (high-avidity T cells) to the
number of IFN-γ-producing cells against 1 μM peptide (total low- and high-avidity T cells). Prevalent high-avidity CD8+ T cells generated after prime-boost immunization, whereas
recombinant vector alone was not effective in induction of functionally active CD8+ T cells in mucosal sites (I, J). To quantify the improvement in CD8+ T-cell avidity in Peyer's patches
and spleen after prime-boost mucosal vs systemic immunizations, we calculated the fold difference in the avidity ratio after prime-boost immunization vs immunization with rMVA
alone in Peyer's patches (I) or spleen (J) after IR vs IM immunizations. rMVA alone was delivered IR for mucosally immunized animals and IM for systemically immunized mice.
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Fig. 2 (continued).
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appear to require DNA priming. In contrast to the PP noted above
(Fig. 2G), a high-avidity ratio was observed in the spleen after
IM prime-boost immunization or immunization with rMVA alone
(Fig. 2H).Fig. 3. Mucosal prime-boost immunization is most effective for high-avidity CD8+ T cells in
vector alone is not sufﬁcient. (A) CD8+ T-cell activity measured as IFN-γ-producing cells by EL
immunization with DNA prime and rMVA boost or rMVA alone. T cells were activated with 1
the number of IFN-γ+ cells against 0.0001 μMpeptide (high-avidity T cells) to the number of I
IM immunizations. The avidity ratio in LP after prime-boost immunization — closed bar and
boost (IR/IR and IM/IM) and criss-cross (IR/IM and IM/IR) immunizations vs immunization w
route of boost in the group of comparison. For IR/IR and IM/IR groups, rMVA was injected ITo quantify the improvement in CD8+ T-cell avidity in Peyer's
patches and spleen after prime-boost strategy after mucosal vs syste-
mic immunizations, we calculated the fold difference in the avidity
ratio after prime-boost immunization vs immunization with rMVA
alone in Peyer's patches or spleen after IR vs IM immunizations. CD8+ T-
cell avidity in Peyer's patches was increased about 10-fold after IR
prime-boost immunization compared to IR immunization with rMVA
alone (pb0.01) (Fig. 2I). There were no increases in CD8+ T-cell avidity
in Peyer's patches after IM prime-boost immunization compare to IM
immunization with rMVA alone (Fig. 2I). Thus, the mucosal prime-
boost regimen is clearly more important for generation of high-avidity
CD8+ T cells in mucosal sites. However, in the spleen, IM and IR prime-
boost immunizations were not signiﬁcantly more effective in genera-
tion of high-avidity CD8+ T cells than rMVA immunization alone
(pN0.05) (Fig. 2J).
Since we observed that the IR prime-boost regimen was optimum
for inducing high-avidity CD8+ T cells at inductive sites of the GALT
(Peyer's patches) we next asked the question whether IR prime-boost
and mismatched routes of prime-boost immunization also induced a
higher proportion of high-avidity IFN-γ secreting CD8+ T cells in the
lamina propria as well, since these cells would need to continuously
disseminate into the effector site of the GALT to confront an incoming
viral infection. To examine CD8+ T cell avidity in the effector site of the
mucosa after IR prime-boost, IR prime-IM boost, IM prime-IR boost
and IM prime-boost immunizations versus animals immunized with
rMVA alone, we evaluated the number of IFN-γ secreting cells in
intestinal lamina propria (LP) after activation with high (1 μM) and
low (0.0001 μM) concentration of P18-I10 peptide (Fig. 3A). Similar
results to those obtained in Peyer's patch (inductive sites) were found.a mucosal effector site (lamina propria), whereas IR immunization with recombinant
ISPOT as a function of peptide concentration for HIV-1 P18-I10 peptide in the LP after IR
μM (closed bar) or 0.0001 μM (open bar) concentration of P18-I10 peptides. (B) Ratio of
FN-γ-producing cells against 1 μMpeptide (total low- and high-avidity T cells) after IR or
rMVA immunization alone— open bar. (C) Fold increase in the avidity ratio after prime-
ith rMVA alone in lamina propria. rMVA alone delivered IR or IM and depending on the
R and for IM/IM and IR/IM, it was given IM.
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were high avidity following IR prime-boost, less than 10% of effector
cells in the lamina propria induced through the IM prime-boost stra-
tegy were high avidity (Fig. 3A). When the prime-boost routes were
mismatched, the IR route of the boost rather than the prime had the
largest impact on CD8+ T-cell avidity in gut mucosa (Fig. 3A). Thus, IM
DNA prime and IR rMVA boost was more effective in generation of
high-avidity CD8+ T cells in the lamina propria than IR DNA prime and
IM rMVA boost (Fig. 3A). However, this demonstrates surprisingly
that even IM DNA priming can cross-prime for high-avidity CD8+ T
cells in lamina propria (Fig. 3A). No signiﬁcant generation of high-
avidity CD8+ T cells was observed in the lamina propria after IR
immunization with rMVA alone or after IM prime-boost or rMVA
alone immunizations (pN0.05) (Fig. 3A). Thus, generation of high-
avidity CD8+ T cells in inductive and effectors sites of the intestinal
mucosa appears to be highly dependent upon a DNA prime-hetero-
logous boost strategy of immunization.
To quantify this CD8+ T-cell avidity difference in the lamina propria
after each prime-boost strategy vs immunizationwith rMVA alone, we
calculated the ratio (%) between the number of IFN-γ secreting cells
against a low P18-I10 peptide concentration and the number of IFN-γ
secreting cells against a high concentration of the P118-I10 epitope
(Fig. 3B). The avidity ratio in LP was signiﬁcantly higher after IR prime-
boost immunization compared to criss-crossed routes, IM prime-
boost immunizations or IR rMVA immunization alone (pb0.01) (Fig.
3B). CD8+ T-cell avidity in lamina propria were increased about 12 fold
after IR prime-boost immunization, compared to IR immunization
with rMVA alone (Fig. 3C). IM prime-IR boost increased lamina propria
CD8+ T-cell avidity about 9 fold, whereas IR prime-IM boost increased
it about 6 fold (Fig. 3C). However, IM prime-boost vaccinationwas not
sufﬁcient to improve CD8+ T-cell avidity in the effector site of the
intestinal mucosa (Fig. 3C). Thus, in contrast to the systemic immune
response, generation of functionally active HIV-1-speciﬁc CD8+ T cells
in the gut mucosa more stringently required the mucosal prime-boost
or IM DNA prime and IR rMVA or rAd boost strategy of immunization.
Discussion
The regimen of immunization for generation of functionally active
and effective CD8+ CTL responses in mucosal and systemic sites is not
well understood (Belyakov et al., 2004a, 2007a; Tatsis et al., 2007). The
current study demonstrates that in mice mucosal prime and boost
immunizations aremore stringently required for the induction of high-
avidity CD8+ T-cell responses in inductive and effector sites of gastro-
intestinal mucosa than for systemic immune responses. Intrarectal
immunization with rMVA alone was not effective in generation of the
most functional CD8+ T cells in the gut mucosa, whereas high-avidity
CD8+ T cells were observed in the spleen after single IR or IM immuni-
zations with rMVA. Thus, we ﬁnd that an IR prime-boost or IM prime-
IR boost strategy ismost effective for induction of high-aviditymucosal
CD8+ T cells as well as for the magnitude of immune responses at
mucosal sites, whereas at systemic sites MVA alone is sufﬁcient to
induce high-avidity CD8+ T cells and the prime-boost immunization is
important primarily for the magnitude of the immune responses.
Generation of HIV-1-speciﬁc CD8+ CTL responses by vaccines may
facilitate efﬁcient control of HIV or SIV replication (Amara et al., 2001;
Barouch et al., 2000; Shiver et al., 2002). Different combinations of
homologous and heterologous prime-boost vaccines are currently
being tested in multiple experiments and clinical trials for AIDS, other
infectious diseases and cancer and hold signiﬁcant promise (Ahlers et
al., 2003; Allen et al., 2000; Amara et al., 2001; Barouch et al., 2000;
Belshe et al., 1998; Berzofsky et al., 2004b; Dale et al., 2006; Gherardi
et al., 2003). A sequential vaccination regimen of priming with DNA
and boosting with recombinant viral vaccines encoding multiple HIV
antigens (Hanke et al., 1998) has proven successful in eliciting robust
CTL responses in multiple animal models as well as humans. Theprime-boost strategy is capable of inducing broad and high levels of
T-cell immunity and ameliorating SIV infection in macaques (Amara
et al., 2001; Barouch et al., 2000; Belyakov et al., 2006b; Neeson et al.,
2006; Shiver et al., 2002). It has also been shown that a heterologous
prime-boost immunization is more effective than a homologous
prime-boost vaccination in the magnitude of the T-cell response, but
the responses did not always correlate with protection. Recently we
evaluated the efﬁcacy of systemic immunization with two human
ALVAC-HIV-1 recombinant vaccines expressing Gag, Pol, and gp120 or
Gag, Pol, and gp160 in a prime-boost protocol with their homologous
vaccine native Env proteins (Pal et al., 2006). The protective efﬁcacy
was studied after mucosal challenge with a high-dose of pathogenic
neutralization-resistant variant SHIV(KU2) (Pal et al., 2006). Systemic
immunization with both vaccine regimens decreased viral load levels
not only in blood but unexpectedly also in mucosal sites and pro-
tected macaques from peripheral CD4+ T-cell loss (Pal et al., 2006).
However, in this study the efﬁcacy of mucosal versus systemic prime-
boost regimen was not evaluated.
Plasmid DNA vaccines and rMVA and rAd vaccines are promising
HIV-1 vaccine candidates, although delivering either vaccine alone
may be inadequate to induce sufﬁcient CD8+ CTL responses for
effective viral control (Amara et al., 2001; Barouch et al., 2000; Shiver
et al., 2002). Very little data exist on the relative immunogenicity of
rMVA or rAd vectors at mucosal sites when administered via mucosal
routes or injected by different regimens (with or without DNA prime).
Casimiro et al. evaluated several DNA vaccine formulations, a rMVA
vector, and a replication-defective adenovirus serotype 5 vector, each
expressing the same codon-optimized HIV-1 gag gene for immuno-
genicity in rhesus monkeys (Casimiro et al., 2003). It was observed
that the DNA vaccine primed T-cell responses most effectively and
provided the best overall immune responses after boosting with Ad5-
gag (Casimiro et al., 2003). However, the mucosal immune responses
after different regimens of immunizations with different recombinant
vectors have not been compared. rAd and rMVA vectors were used in
prime-boost vaccine regimens to address the effect of repeated
immunizations on transgene product-speciﬁc CD8+ cell frequencies in
systemic (spleen, blood, lymph nodes, and peritoneal lavage) and
mucosal (mesenteric lymph nodes, intestinal epithelium, and Peyer's
patches) lymphoid tissues (Tatsis et al., 2007). It was found that
multiple dose vaccine regimens have increased functionally active
transgene-speciﬁc T cells and improve the levels of activated T cells in
the gut mucosa (Tatsis et al., 2007). The recent study demonstrates
that a single oral immunizationwith a chimpanzee derived adenoviral
vector expressing HIV gag was inefﬁcient at eliciting responses in the
mesenteric lymph nodes and Peyer's patches, while a single intra-
muscular administration elicited strong systemic and detectable
mucosal responses (Lin et al., 2007). However, the different routes of
mucosal vaccination (IR route for example) and functional avidity of
mucosal CD8+ T cells were not characterized in this study. Our study
demonstrated that a mucosal prime-boost or intramuscular DNA
mucosal vector boost with rMVA or rAd in which the DNA priming is
mucosal or systemic but the viral vector boost is mucosal, is effective
in generation of mucosal HIV speciﬁc CD8+ CTL in gut mucosal sites.
However, IM vaccination was less effective in induction of antigen-
speciﬁc CD8+ T cells in the intestine.
Optimal routes and numbers of vaccinations for generation of
functionally active and effective CD8+ CTL are not well understood
especially for mucosal CTL. A recent study by Masopust et al. demon-
strated that memory T-cell phenotype differed substantially depend-
ing on the number of immunizations. Prime-boost vaccination strategy
resulted in the generation of effector memory CD8+ T cells with pre-
ferential accumulation in nonlymphoid tissues (Masopust et al., 2006).
In another prime-boost study by Evans et al. (2003) it was shown that
oral immunization with recombinant Salmonella and boosting with
rMVA induced a high level of the intestinal homing receptor α4β7 on
peripheral blood lymphocytes and improved control of virus
112 I.M. Belyakov et al. / Virology 381 (2008) 106–115replication following a rectal challenge with SIVmac239. Thus,
protection against rectal or vaginal challenges was dependent on
robust mucosal immunity, and mucosal routes of vaccination gener-
ated these protective immune responses.
Our results suggest several possible explanations for the efﬁcacy of
criss-crossed prime-boost. Mixed prime-boost immunization strate-
gies may activate T cells in mucosal inductive sites with different
efﬁcacy with acquisition of different levels of expression of the inte-
grin α4β7 and the chemokine receptor CCR9. These molecules are
important for their subsequent localization to the small intestine. DCs
are important for the induction of tissue tropic effector T-cell subsets
(Johansson-Lindbom and Agace, 2007). For example, MLN or PP DC's
are necessary and sufﬁcient for the generation of CCR9+α4β7+CD62L−
gut-homing T cells in vitro and mucosal DCs (not systemic DC) were
able to convert dietary vitamin A to retinoic acid, which in turn
induced T-cell expression of CCR9 and α4β7 (Iwata et al., 2004;
Johansson-Lindbom and Agace, 2007; Saurer et al., 2007). After syste-
mic DNA prime, a strong mucosal boosting immunization (with rMVA
vector) may provide TLR ligands that activate mucosal DCs and induce
a strong proliferation of T-cell precursors derived from systemic DNA
priming or result in release of chemokines that attract T cells to the
mucosal site. Also a strong rMVA boosting will help migration
(“migratory gut environment”) of activated T cells from inductive
lymphoid tissues to the effector non-lymphoid mucosal sites. In any
case, with the recognized need for both mucosal and systemic CTL, a
criss-cross heterologous prime-boost strategymay be an effectiveway
to achieve both goals.
Functional impairment of antigen-speciﬁc CD8+ CTL has been
associated with clinical AIDS progression (Acierno et al., 2006; Appay
et al., 2000; Hel et al., 2001a; McKay et al., 2002). CD8+ CTL that can be
activated by low concentrations of peptide are deﬁned as high-avidity
CD8+ CTL, while those that recognize peptide/MHC only at high
antigen concentration are termed low-avidity CD8+ CTL (Alexander-
Miller et al., 1996; Belyakov et al., 2006b; Snyder et al., 2003). It is very
clear now that high-avidity CD8+ CTL are essential for elimination of
tumor (Yee et al., 1999; Zeh et al., 1999) and more effective in vivo in
protection against viral infection (Alexander-Miller et al., 1996;
Belyakov et al., 2007a, 2006b; Derby et al., 2001; Estcourt et al.,
2002; Gallimore et al., 1998). Recently we demonstrated that a
mucosal prime-boost vaccine inducing high levels of high-avidity
mucosal CTLs can have an impact on dissemination of intrarectally
administered pathogenic SHIV-ku2 and such protection correlates
better with mucosal than systemic CTLs and particularly with levels of
high-avidity mucosal CTLs (Belyakov et al., 2006b). In a recent study
by Ranasinghe et al. the avidity of HIV-speciﬁc CD8+ CTL generated by
mucosal and systemic poxvirus prime-boost vaccines were evaluated.
It was demonstrated that mucosal HIV-1 recombinant homologous
poxvirus prime-boost immunization induces high-avidity CD8+ T cells
with high expression of granzyme B mRNA in genital mucosa
(Ranasinghe et al., 2007). The I.N. prime-I.M. boost group elicited a
higher number of CTL-expressing granzyme B mRNA from the
genitomucosal sites compared with the I.M. prime-boost regime.
Also CTL generated after both I.N. or I.M. vaccination expressed Th2
cytokine IL-4 mRNA, although lower numbers were observed after I.N.
prime-boost immunization (Ranasinghe et al., 2007). Similarly we
found an inﬂuence of the route of immunization on generation of
functionally active CD8+ T cells (Belyakov et al., 2007a). We compared
the effect ofmucosal and systemic immunization for induction of high-
avidity CD8+ CTL at the local sites of immunization vs distally in mice
and macaques (Belyakov et al., 2007a). The optimum vaccine strategy
for the inductionof high-avidity CTL at bothmucosal and systemic sites
has to our knowledge never been demonstrated before, and now
requires some additional pre-clinical testing in SIVmodel inmacaques.
The current study demonstrates that, for generation of functionally
active mucosal CD8+ T cells in mice, a heterologous mucosal prime-
boost regiment is most effective. A single mucosal immunization witha recombinant vector is not sufﬁcient for induction of a high level of
high-avidity CD8+ Tcells in the intestine, whereas it is at systemic sites.
The requirement for a heterologous prime-boost strategy for genera-
tion of high-avidity CD8+ T cells in mucosal sites is much more
stringent than for induction of high-avidity CD8+ T cells in systemic
lymphoid tissues. Further, we ﬁnd that systemic DNA priming is
sufﬁcient to induce high-avidity mucosal CD8+ T cells if the heterolo-
gous viral vector boost is delivered mucosally, in a criss-cross strategy.
Materials and methods
Mice
Female BALB/c mice were purchased from the Frederick Cancer
Research Center (Frederick, MD).
Recombinant viruses
MVA/HXB2env was constructed as follows: the HXB2 env gene,
truncated by 104 amino acids to yield a C-terminal sequence of
SIRLVNGS, was cloned into shuttle plasmid pLW24. This plasmid
directs recombination into deletion III of MVA utilizing the P7.5 early/
late promoter. The recombinant modiﬁed vaccinia Ankara (rMVA) was
produced using standard techniques (Earl et al., 1998; Wyatt et al.,
2008). Live immunostaining using rabbit sera R2144 produced against
HIV env, was used for plaque screening.
Recombinant adenovirus (rAd) was constructed as follows: the
clade B Env cDNA is a gp140 chimera derived from HXB2 with trans-
position of theV3 region fromHIV-1 Balwithmutations in the cleavage
site, fusion peptide, and interhelical domain (DCFI) and prepared as
previously described (Chakrabarti et al., 2002). The insert was
introduced into a rAd5 vector and prepared by standard methods
(Huang et al., 2001; Letvin et al., 2004). Virus was puriﬁed by cesium
chloride centrifugation and stored at 1010 particles per ml in phos-
phate-buffered saline.
Vaccine and immunizations
Six groups of 5 BALB/cmice per groupwere immunized in different
combinations by different routes in a heterologous DNA prime viral
vector boost strategy. Group 1) DNA and recombinant vector IM; 2)
DNA given IR and recombinant vector injected IM; 3) DNA given IM
and recombinant vector injected IR; 4) DNA and recombinant vector
IR. Group 5) Animals received DNA immunization only and Group 6
and 7) a single immunization with either recombinant vaccinia virus
or recombinant adenovirus. For the DNA immunizations mice were
injected IM with 50 μg of plasmid DNA in the quadriceps muscle at
3 week intervals between each immunization, for a total of three
injections and boosted once with recombinant MVA (107 pfu) or
recombinant Adenoviral vector (1010pfu). For IR immunization
plasmid DNA (50 μg) was complexed with the cationic lipid DOTAP
(50 μg) by vigorous mixing by vortex. For recombinant viral immu-
nization, virus was diluted to the appropriate titer (pfu) in sterile
phosphate-buffered saline (PBS), and 150 μl of the virus inoculum
injected IR through an umbilical catheter inserted about 4 cm deep
while mice were under inhalation anesthesia (methoxyﬂurane; Pit-
man-Moore, Inc., Mundelein, IL) (Belyakov et al., 1999, 1998c). Mice
were boosted with rMVA (1×107 pfu) or the replication-deﬁcient
adenoviral vector (1010 pfu) encoding each antigen injected IR or IM.
The DNA-rMVA or DNA-rAd boost animals were injected with 50 μg
DNA IR or IM as described above, followed by the rMVA or rAd boost
3 weeks after the third plasmid DNA injection. The optimum
immunodominant CTL epitope P18-I10 peptide (RGPGRAFVTI) from
the V3 loop of the HIV-1IIIB envelope protein presented by H-2Dd in
BALB/c mice (Takahashi et al., 1988) was synthesized on an automated
peptide synthesizer (Symphony Multiplex; Rainin, Boston, Mass) and
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from Neo MPS (San Diego).
Cell puriﬁcation
Three weeks after the last immunization, antigen-speciﬁc T cells
were isolated from Peyer's patch (PP), lamina propria (LP), and spleen
(SP). The PP were carefully excised from the intestinal wall and
dissociated into single cells by using collagenase type VIII, 300 U/ml
(Sigma) as described previously (Belyakov et al., 1998b). Our data
showed that the predominant CD3+ T cells isolated from PP of normal
micewere CD4+ (25%), while CD3+ CD8+ Tcells were less frequent (8%).
Collagenase type VIII did not alter expression of CD3, CD4, or CD8
splenic T cells treated with this enzyme. LP lymphocyte isolation was
performed as described previously, typically recovering over 2×106
viable LP lymphocytes per mouse (Belyakov et al., 1998b). The large
and small intestines were dissected from individual mice and mesen-
teric and connective tissues carefully removed. Fecal material was
ﬂushed from the lumen with RPMI 1640 medium. After the PP were
removed from the intestinal wall, the intestines were opened
longitudinally, cut into short segments, and washed extensively in
RPMI 1640 medium containing 2% fetal bovine serum. To remove the
epithelial cell layer, tissues were placed into 100 ml of 1 μM EDTA and
incubated twice (ﬁrst for 40 min and then for 20 min) at 37 °C with
stirring. Following EDTA treatment, tissues were washed in complete
RPMI 1640 medium for 10 min at room temperature and then placed
into 50 ml of RPMI medium containing 10% FCS and incubated for
15 min at 37 °C with stirring. The tissues and medium were trans-
ferred to a 50 ml tube and shaken vigorously for 15 sec, and then the
medium containing epithelial cells was removed. This mechanical
removal of cells was repeated twicemore, by using freshmedium each
time, to completely remove the epithelial cell layer. Histologic exami-
nation revealed that the structure of the villi and LP were preserved.
To isolate LP lymphocytes, tissue were cut into small pieces and
incubated in RPMI 1640 medium containing collagenase type VIII,
300 U/ml (Sigma) for 50 min at 37 °C with stirring. Supernatants
containing cells were collected, washed and then resuspended in
complete RPMI 1640medium. This collagenase dissociation procedure
was repeated two times and the isolated cells pooled and washed
again. Cells were passed through a cotton wool column to remove
dead cells and tissue debris and then layered onto a discontinuous
gradient containing 75% and 40% Percoll (Pharmacia). After centrifu-
gation (4 °C, 600×g, 20 min), the interface layer between the 75% and
40% Percoll was carefully removed and washed with incomplete
medium. SP were aseptically removed and single cell suspensions
prepared by gently teasing them through sterile screens. The
erythrocytes were lysed in Tris-buffered ammonium chloride and
the remaining cells washed extensively in RPMI 1640 medium
containing 2% fetal bovine serum (Belyakov et al., 2003).
CTL assay
We measured the CD8+ CTL response by 51Cr-release assay, 7 days
after in vitro stimulation with P18-I10-peptide in the spleen and
Peyer's patches. Immune cells from SP, PP were cultured with or
without the P18-I10 peptide (1 μM) at 5×106/ml in 12-well culture
plates in complete T cell medium: RPMI 1640 medium containing 10%
fetal bovine serum, 2 mM L-glutamine, penicillin (100 U/ml),
streptomycin (100 mg/ml), and 5×10−5 M 2-mercaptoethanol. After
3 days we added medium containing 10% ConA-stimulated spleen cell
supernatant (T-stim; Collaborative Biomedical Products, Bedford, MA)
as a source of IL-2. Speciﬁc T cells were found to increase 3–7 fold
during the 7-day culture. Cytolytic activity of CD8+ CTL was measured
by a 4-h assay with 51Cr-labeled P815 targets tested in the presence or
absence of P18-I10 peptide (1 μM). For testing the peptide speciﬁcity of
CTL, 51Cr-labeled P815 targets were pulsed for 2 h with peptide at thebeginning of the assay(Ahlers et al., 2001). The percent speciﬁc 51Cr
release was calculated as 100×(experimental release-spontaneous
release) / (maximum release-spontaneous release). Maximum release
was determined from supernatants of cells that were lysed by
addition of 5% Triton X-100. Spontaneous release was determined
from target cells incubated without added effector cells (Belyakov
et al., 2004b).
IFN-γ ELISPOT assay performed on mouse splenocytes, PP and LPL
Lymphoid cells were cultured in the wells of a 96-well ELISPOT
plate in a volume of 200 μl, at 1×105 lymphoid cells/well. Splenocytes
from naive BALB/c mice were used as stimulator cells (2×105/well),
pulsed in complete media for at least 1 h with different concentra-
tions of P18-I10 peptide (RGPGRAFVTI), washed with complete media
twice, gamma-irradiated (3000R) and then added to cultures
containing lymphocytes from the spleen, PP and LP isolated from
immunized mice. The plates were incubated for at least 18 h at 37 °C
in 5% CO2 and air. Overnight incubation of T cells with peptide allows
the functional assessment of CD8+ T cells (which cannot be detected
ex vivo from freshly isolated cells) without changing the absolute
number of antigen-speciﬁc CD8+ T cells as measured by tetramer
staining or the repertoire of TCR analyzed with mAb (Belyakov et al.,
2001b). After that, the plates were washed thoroughly with PBS–
0.05% Tween 20 (Sigma) followed by incubation with rat anti-mouse
IFN-γ biotinylated monoclonal R4-6A2 (2 μg/ml; Mabtech) in PBS–
0.5% BSA for 3 h at 37 °C. After incubation with secondary mAbs,
plates were washed with PBS–0.05% Tween 20, and incubated with
alkaline phosphatase substrate prepared from VECTASTAIN Elite ABC
Kit (Vector Laboratories, Inc) for 1 h at room temperature. At the last
stage, plates were washed with PBS–0.05% Tween 20 followed by PBS
and developed with BD™ ELISPOT AEC Substrate Set (Pharmingen).
Spots were counted on an AID ELISPOT Reader (Cell Technology, Inc.)
(Belyakov et al., 2007a). Background levels of IFN-γ-producing cells
measured on total lymphoid cell populations with no antigen
stimulation were substracted from the experimental groups as pre-
viously described (Belyakov et al., 2006a).
Statistical analysis
Statistical comparisons were performed using Student's t-tests
(Kuznetsov et al., 2004). The pre-determined level of signiﬁcance was
set at a p value of b0.05.
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